Reveal Pharmaceuticals, Inc, based in Cambridge, MA, is a medical technology company dedicated to transforming medical insight while prioritizing the health of people and the planet. They are focused on developing gadolinium-free contrast-enhanced MRI agents, such as RVP-001, which is designed to be a direct replacement for current standard of care MRI contrast agents, based on manganese, a trace element essential for life. Additionally, Reveal is pioneering the development of fibrogenesis imaging agents, with potential applications for diagnosis, staging, patient stratification, and monitoring response to treatment in various fibrotic diseases.
Led by CEO and Co-Founder Vera Hoffman, who has extensive experience in directing startups and high-growth enterprises, Reveal is supported by a team of experts including Co-Founder Professor Peter Caravan, a world leader in MRI contrast agent development, and Co-Founder Assistant Professor Eric Gale, who applies chemistry to solve challenges in radiology and biomedical imaging. With a focus on innovation and clinical translation, Reveal aims to revolutionize medical imaging and contribute to the advancement of healthcare.
Generated from the website